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Abstract
Nm23-H1 is a well-known tumor metastasis suppressor, which functions as a nucleoside-
diphosphate kinase converting nucleoside diphosphates to nucleoside triphosphates with an 
expense of ATP. It regulates a variety of cellular activities, including proliferation, development, 
migration and differentiation known to be modulated by a series of complex signaling pathway. 
Few studies have addressed the mechanistic action of Nm23-H1 in the context of these cellular 
processes. To determine the downstream pathways modulated by Nm23-H1, we expressed Nm23-
H1 in a Burkitt lymphoma derived B-cell line BJAB and performed pathway specific microarray 
analysis. The genes with significant changes in expression patterns were clustered in groups which 
are responsible for regulating cell cycle, p53 activities and apoptosis. We found a general 
reduction of cell cycle regulatory proteins including cyclins and cyclin dependent kinase inhibitors 
(anti proliferation), and upregulation of apoptotic genes which included caspase 3, 9 and Bcl-x. 
Nm23-H1 was also found to upregulate p53 and downregulate p21 expression. A number of these 
genes were validated by real time PCR and results from promoter assays indicated that Nm23-H1 
expression downregulated cyclin D1 in a dose responsive manner. Further, we show that Nm23-H1 
forms a complex with the cellular transcription factor AP1 to modulate cyclin D1 expression 
levels. BJAB cells expressing Nm23-H1 showed reduced proliferation rate and were susceptible to 
increased apoptosis which may in part be due to a direct interaction between Nm23-H1 and p53. 
These results suggest that Nm23-H1 may have a role in the regulation of cell cycle and apoptosis 
in human B-cells.
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Introduction
The nm23 gene family is a closely related group of nucleoside diphosphate kinases for 
which eight distinct genes are known in humans (Nm23-H1 to H8).1 Traditionally, 
Nm23/NDP kinases were ascribed a single physiological function, namely the synthesis of 
nucleoside triphosphates, other than ATP.2 However mounting evidence now suggests that 
these proteins are multifunctional with diverse biological roles that include differentiation,3 
proliferation4 and development.5 The nm23-H1 gene is the first known gene shown to 
regulate tumor metastasis and was identified using differential hybridization analysis 
between murine K-1735 melanoma cell lines that varied in metastatic potential in vivo.6 The 
expression of Nm23-H1 is divergent in malignant tumors; however there is sufficient data 
indicating that increased levels of Nm23-H1 correlated with decreased metastasis in most 
cancers including breast, gastric and cervical cancers.6 This data is supported by in vivo 
studies carried out in mice lacking the nm23-M1 gene, the murine homologue of nm23-H1.7 
Nm23-M1 knockout mice had a significantly higher incidence of lung metastases compared 
to nm23-M1+/+ mice, when these mice were induced to develop hepatocellular carcinoma.8 
However, it appears that the anti-metastatic effects of Nm23-H1 are independent of the 
tumor cell growth rate as the primary tumor size of the knockout mice did not change 
significantly.7
Although the nm23 family of genes has been studied extensively for more than a decade, the 
exact mechanism whereby Nm23-H1 suppresses metastasis has yet to be fully defined. Most 
studies have focused on its ability to inhibit motility using in vitro assays, as the ability to 
migrate is the hallmark of metastasis. Overexpression of Nm23-H1 almost abolished the cell 
motility of human MDA-MB-435 cell line in response to multiple chemo-attractants and 
reduced their anchorage-independent growth and invasion.9 This was also found to be true 
for other cell lines including cell lines of colon and prostate carcinoma origin.10 When 
injected into nude mice, Nm23-H1 expressing MDA-MB-435 cell line produced metastasis 
in significantly fewer mice than the control cell lines.11
Biochemically, the metastasis suppressing function of Nm23-H1 is independent of its NDP 
kinase enzymatic activity.12 However, its histidine protein kinase activity may contribute 
towards suppression of motility as revealed by the mutational analysis of Nm23-H1. 
Transfection of substitution mutants P96S and S120G which were deficient only in 
histidine-dependent serine auto-phosphorylation did not inhibit the motility and invasion of 
MDA-MB-435.13 Recent studies indicate that stimulation of phosphodiesterase activity may 
also correlate with the ability of Nm23-H1 to suppress MDA-MB-435 cell motility.14
Nm23 has been shown to interact with several proteins including the integrin cytoplasmic 
domain-associated protein 1α (ICAP-1α),15 the prune protein (Pn),16 the centrosomal 
kinase Aurora-A/STK15,17 the Lbc proto-oncogene,18 intermediate filaments,19 map 
kinases20 and telomeres.21 Although the biological significance of these interactions is not 
very well characterized, these studies clearly suggest that Nm23-H1 may target multiple 
downstream pathways.
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Nm23-H1 can modulate the gene expression in several ways. It was found to repress the 
transcription of platelet-derived growth factor (PDGF-A) promoter through DNA binding to 
nuclease-hypersensitive transcriptional elements.22 The C-terminal half of Nm23-H1 
exhibits strong transactivation activity in Gal4 transcriptional assays.23 Previous studies in 
our laboratory also suggested that Nm23-H1 can function through interaction with cellular 
factors like Dbl.24 The objective of this study was to explore the role of Nm23-H1 during 
malignant transformation of the human B cells by identifying genes, groups of genes or 
signaling pathways targeted by Nm23-H1. We compared the gene expression profiles of 
BJAB cells stably transfected with a myc tagged Nm23-H1 expression construct, with the 
vector alone transfected cells as a control. The results obtained from the DNA microarrays 
analysis confirmed the significance of some pathways previously reported, but also opened 
new questions about the functional role of Nm23-H1 in regulating different cellular events in 
normal and malignant transformed cells as well as the potential for development of 
therapeutic strategies in tumor regression.
Results
Characterization of nm23-H1 transfected cell lines and genes associated with Nm23-H1 
expression in BJAB cell line
BJAB (vector control) and BJAB (pA3M-Nm23-H1) cell phenotypes are not distinguishable 
by morphologic variations. To determine the expression of Nm23-H1 in specific cell lines, 
before initiating the microarray experiments, we verified the expression of RNA and 
corresponding protein levels of the nm23-H1 gene in two clones C#6 and C#10 and showed 
that both clone 6 and 10 were expressing nm23-H1 although clone 10 was more robust in its 
expression (Fig. 1, Left). Gene expression of vector control profile BJAB cell line was 
compared with that of BJAB clones expressing nm23-H1 from an exogenous promoter by 
Oligo GE array. The expression profile of different genes identified within specific cellular 
pathways revealed the possible involvement of some previously well characterized genes. 
We used three different pathway specific arrays named p53, cell cycle and apoptosis oligo 
GE array (Fig. 1, Right). The data clearly shows downregulation of the majority of apoptotic 
genes up to about 70%, and close to 80% of the genes upregulated shown to be involved in 
cell cycle proliferation. Some genes responsible for p53 dependent cell cycle arrest were 
also found to be upregulated (Fig. 1, Right). These results were validated for a number of 
these genes by semi quantitative real time PCR. A number of these genes that were found to 
be up or downregulated by significant levels after normalization are shown in Table 1. In fact 
some of these genes significantly upregulated included the caspases 3 and 9, tumor necrosis 
factor receptor superfamily member 25 and the p53 tumor suppressor as well as the regulator 
Bcl2 associated X protein. Additionally, we saw a dramatic decrease in levels of cyclins and 
cyclin associated proteins (Table 1). These proteins were all associated with regulation of 
cell proliferation and survival in the nm23-H1 expressing BJAB cell clones investigated 
suggesting an important role of nm23-H1 in contributing to these activities. We decided to 
focus our efforts on CyclinD1 and p53 as we were able to easily obtain reagents to validate 
and study the regulation of their expression in this setting.
Choudhuri et al. Page 3
Cancer Biol Ther. Author manuscript; available in PMC 2018 May 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Nm23-H1 reduces transcriptional activity of the cyclin D1 promoter in human cells
Previous studies have shown that Nm23-H1 can function as a transcription factor in 
regulating gene expression.25 The microarray data and the subsequent Real Time PCR 
validation showed that Cyclin D1 similar to other cyclins was clearly downregulated. The 
effect of Nm23-H1 expression on the promoter activity of full length Cyclin D1 promoter 
cloned into pGL2 basic vector was assessed by luciferase reporter assay. The expression 
vector pA3M-Nm23-H1 along with either the empty pGL2 vector, or pGL2 with Cyclin D1 
promoter were transfected in BJAB, DG-75 and 293 cell lines. The total amount of DNA in 
each transfection was normalized by adding the appropriate amount of empty vector. The 
results from this assay demonstrated that the Nm23-H1 effectively downregulated the Cyclin 
D1 promoter in a dose-dependent manner in the three cell lines which were tested (Fig. 2A). 
Nm23-H1 expression was confirmed by western blot using specific antibodies against the 
myc epitope tag which was fused in frame at the carboxy terminus to the nm23-H1 open 
reading frame. Interestingly, the level of repression was more dramatic in the B cell lines 
compared to the epithelial cell line 293 to about 2-fold greater based on the data obtained.
The cellular transcription factor AP1 is important for modulation of the cyclin D1 promoter
To date, Nm23-H1 has not been shown to regulate transcription by directly binding DNA. 
Therefore we focused our attention on transcription factors which were likely to be targeted 
by Nm23-H1 as has previously been shown for regulation of the specific promoter like 
integrins, MMP 9 and Cox2.26–28 Transcription factor AP1 and Sp1 have been previously 
shown to activate Cyclin D1 expression.29,30 The pGL2-Cyclin D1 promoter reporter 
plasmid with targeted deletions which removed the Sp1, AP1 and E2F-1 binding sites were 
used in luciferase reporter assays (Fig. 2B). The results of these assays showed that the 
reporter constructs deleted for AP1 had little or no apparent change in activity when 
compared with the vector alone control. However, when assayed in the context of Nm23-H1 
expression, an approximately 50% reduction in the transcription activity levels was seen 
(Fig. 2B and compare lines 1 with 4, 5 and 6). To further address the role of AP1, we 
generated truncated deletions of the cyclin D1 promoter reporter element here the AP1 
transcription binding site was clearly deleted and when the activities were compared to the 
AP1 specific mutated reporter promoter plasmid the results showed that there was negligible 
change in the activity in the presence of Nm23-H1 in the three cell lines (Fig. 2B and 
compare lanes 4 with 5 and 6).
Nm23-H1 forms a complex with the cellular transcription factor AP1
The results of the luciferase reporter promoter assays above indicated that the AP1 binding 
sites within the cyclin D1 promoter were critical for Nm23-H1-mediated downregulation. 
Therefore, we performed an electrophoretic mobility shift assay (EMSA) to determine if 
Nm23-H1 and AP1 formed a complex with each other bound to the cis-acting DNA binding 
site for AP1. In addition specific antibodies against AP1 and myc-Nm23-H1 were also used 
to supershift the specific complex containing AP1 and myc-Nm23-H1. The results of the 
EMSA showed that a shift specific for AP1 was observed when nuclear extract was added 
with labeled AP1 specific probe indicating that the AP1 transcription factor can bind to its 
specific cis-acting element at the Cyclin D1 promoter (Fig. 3A, lane 2). The AP1 specificity 
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of the shift was confirmed because we did not see a specific shift when we used the mutant 
AP1 (Fig. 3A and compare lanes 1, 2 and 3). Furthermore, the specificity of this shift was 
also verified through the disappearance of the shift in the presence of specific cold 
competitor probe (Fig. 3A and compare lanes 1, 2 and 4). Importantly, the shift was not 
disrupted when we used a non-specific cold competitor probe (Fig. 3A, lane 5). In addition, 
the mobility of the AP1 probe was also reduced in the presence of in vitro translated myc-
Nm23-H1 protein (Fig. 3A lane 6). A similar shift as the AP1 shift was seen when we used 
unprogrammed rabbit reticulocytes which was used as a control (Fig. 3A, lane 7). The 
presence of Nm23-H1 in the complex was verified by addition of anti-myc antibody to 
complex with the myc tagged Nm23-H1 protein resulting in super-shifting of the AP1 probe 
(Fig. 3A, lane 8). The addition of AP1-specific antibody also showed a specific supershift 
indicating the presence of AP1 in the complex (Fig. 3A, lane 9). The antibody specificity 
was shown when we use anti IgG control antibody and no supershift was observed (Fig. 3A 
and compare lanes 8, 9 and 10). These results suggest that Nm23-H1 can target AP1 bound 
to the distinct AP1 element within the Cyclin D1 promoter and therefore may regulate 
expression through interaction with one or more factors which is bound to the promoter 
element.
To determine if Nm23-H1 in fact can form a complex with AP-1 bound to its cis-acting 
DNA element within the cyclin D1 promotor. We performed chromatin immunoprecipitation 
(ChIP) analysis using anti-myc specific antibody as Nm23-H1 was tagged with the myc 
epitope. The results from the ChIP analysis indicated that myc tagged Nm23-H1 was in a 
complex with AP-1 as amplification of the AP-1 binding sequences showed positive signals 
(Fig. 3B). As expected, specific signals were obtained from total chromatin used as input as 
well as chromatin immunoprecipitated with anti myc-Nm23-H1 antibody. However, no 
signal was seen when control antibody was used (Fig. 3B compare lane 1 and 2 with lane 3).
Nm23-H1 enhances the transcriptional activity of a multimerized p53 responsive cis-acting 
DNA element in human cell lines
Approximately 60% of the genes from the p53 related pathway gene array were upregulated. 
Can Nm23-H1 modulate the transcriptional activity at p53 responsive genes? Therefore 
BJAB, DG-75 and 293 cells were co-transfected with the pG13 promoter construct 
containing the p53 cis-acting elements with increasing amounts of the Nm23-H1 expression 
construct. Vector control was used to normalize the total DNA being transfected. Results 
from this assay showed a dose dependent increase in luciferase activity in all three cell types 
(Fig. 4). There was a consistent pattern of increase between 25–40 fold activity in terms of 
RLU in these cells. The EBV negative B cell line DG75 showed the most characteristic 
increase with an approximately 40 fold level of activation (Fig. 4). Therefore, Nm23-H1 
expression can lead to an increase in p53 transcription as seen by in vitro luciferase assay 
(Fig. 4). The results from in vitro luciferase assays clearly show that Nm23-H1 expression 
can lead to a dramatic increase in activation of the p53 responsive element suggesting that 
Nm23-H1 can activate the promoter possible through interaction with p53 and possibly 
additional factors which may form a complex with p53 bound to its cis-acting element.
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Nm23-H1 directly binds to the carboxy-terminal domain of the p53 tumor suppressor
Our microarray analysis of the Nm23-H1 expressing BJAB cells demonstrated upregulation 
of p53 levels in BJAB cells (Table 1), which was validated by semi quantitative real time 
PCR. In addition the above transcription analyses suggested that Nm23-H1 may associate 
with p53 in complex with its binding element. To determine if there was an association 
between Nm23-H1 and p53, co-immunoprecipitation was performed in BJAB and 293 cells 
expressing Nm23-H1 and p53 from a heterologous system. Nm23-H1 tagged with the HA 
epitope was co-immunoprecipitated with myc tagged p53 in both cell types using anti-myc 
antibodies for immunoprecipitation (Fig. 5). This finding was corroborated by GST pull 
down assays using in vitro-translated Nm23-H1 protein labeled with 35S-Met/Cys mixture 
(Fig. 5). The labeled protein was incubated with a number of truncated mutants of GST-p53, 
as well as the full-length GST-p53 to map the binding region. The results of the binding 
assays indicate that the region of p53 that directly interacts with Nm23-H1 lies between 
amino acids 100 and 300, which primarily includes the DNA binding domain of p53 (Fig. 
5). Importantly, the region of p53 between residues 300–393 also bind to Nm23-H1, which 
includes its basic domain and oligomerization domain. Additionally, the data indicated that 
the amino terminal region comprising amino acid 1–80 of p53 is not involved in binding, as 
there was little or no detectable interaction seen with Nm23-H1 (Fig. 5). Importantly, the 
luciferase control showed negligible binding to p53 fusion protein. Therefore, these results 
clearly show that Nm23-H1 directly interacts with p53 through its DNA binding domain and 
may also interact albeit with lesser affinity with the oligomerization domain. This is distinct 
from previous studies which show association with p53 in complex in the cells.31
Cell expressing Nm23-H1 has reduced proliferation and are prone to apoptosis
Since, we noticed decreased expression of cyclin D1 and p21, and an increased expression 
of p53 in Nm23-H1 expressing cell lines from our screen, we further wanted to correlate 
these findings with relevant biological and functional significance linked to cyclin D1 and 
p21 as well as p53 expression. The obvious corollary of these findings based on the 
functional relevance of these proteins, will be the decreased proliferation rate and increased 
susceptibility to apoptosis in cells expressing Nm23-H1. To determine whether or not, 
Nm23-H1 expressing cells would be more prone to apoptosis, we plated an equal number of 
BJAB cells expressing either pA3M-Nm23-H1 or pA3M vector control for 48 h and stained 
them with 7ADD. The data from the analysis showed that approximately 40% of cells 
expressing the YFP-Nm23-H1 protein took up the 7AAD stain compared to no detectable 
uptake in the vector control cell lines (Fig. 6A). The results of these data imply that cells 
expressing Nm23-H1 were significantly more prone to induction of apoptosis when 
compared to vector control. Moreover, we saw the same pattern when we performed the 
experiment in the background of other cell lines like DG75 and 293 cells (Fig. 6A, Lower). 
Therefore Nm23-H1 expressing cells were found to have a greater propensity for apoptosis 
when tested in three different cell lines independently.
Next we investigated the proliferation potential of BJAB cells stably expressing Nm23-H1 
and compared it to cells containing vector alone using carboxyfluorescein diacetate 
succinimidyl ester (CFSE) assay. As a control for CFSE staining, BJAB cells were serum 
starved. The results showed that these cells had increased uptake of CFSE compared to 
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BJAB vector control, which was shifted to the left. This indicated a greater level of 
proliferation in BJAB vector control cells when compared to the isogenic background cell 
line BJAB Nm23-H1 (Fig. 6B). The BJAB cells expressing Nm23-H1 had an increased level 
of CFSE uptake suggesting a definite decrease in the proliferation. Similar results were 
observed for multiple clones of Nm23-H1-BJAB and when using DG75 repeated and 293 
cells (data not shown).
Nm23-H1 can promote apoptosis in a p53 dependent manner
To investigate whether increased Nm23-H1 expression can induce apoptosis through 
utilization of the p53 dependent pathway, we used doxycycline-regulated knockdown of 
wild-type p53 expressing 293 cell lines. In the absence of doxycycline, the shRNA specific 
for p53 was expressed and the cells showed knockdown of p53 protein levels. Whereas in 
the presence of doxycycline, the shRNA specific for p53 was not produced resulting in 
expression of wild type p53 at endogenous levels (Fig. 7). We checked the status of two 
downstream targets of p53 i.e., Bax and p21.32–34 Both of these molecules were 
undetectable when the p53 specific shRNA was induced to knockdown endogenous p53. 
Additionally, when we transfected these cells with Nm23-H1, the p21 and Bax expression 
remained undetectable (Fig. 7A). However, upon doxycycline induction, the expression of 
the p53 specific shRNA was shut off and resulted in expression of wild-type p53 with a 
simultaneous increase in Bax and p21 (Fig. 7A, right). Bax along with p21 expression in the 
p53-expressing cells showed a dramatic increase in protein levels with increased expression 
of Nm23-H1 (Fig. 7A). To demonstrate that p53 is specifically involved in Nm23-H1-
induced apoptosis, we used the p53-null cell line SAOS-2.35 In these p53-null cells, an 
increase in Nm23-H1 expression failed to induce apoptosis (Fig. 7B). However, when we 
introduced wild type p53 in the SAOS2 cell line from an exogenous system, apoptosis was 
observed in about 7% of the cells. Furthermore co-transfecting the SAOS2 cells with both 
p53 and YFP-Nm23-H1 resulted in a relatively high amount of approximately 22% of the 
cells undergoing apoptosis. These results strongly suggest that enhanced Nm23-H1 
expression induces apoptosis through a p53-dependent mechanism.
Discussion
Nm23-H1 mediated suppression of metastasis is a well documented phenomenon. However, 
recent studies implicate Nm23-H1 in other aspects of carcinogenesis including anchorage 
independent growth and promoting tumor cell differentiation.36 It seems likely that Nm23-
H1 mediates signaling that involves the coordinated regulation of multiple cellular genes and 
pathways. As mentioned earlier in this text the complete picture of functions, targets, and 
partners of Nm23-H1 is still incomplete. Different groups of investigators have reported its 
involvement in cell proliferation, differentiation, signaling and other cellular events.
24,26–28,37
 Moreover, earlier studies have also reported Nm23-H1 modulation of cellular 
gene expression.26,38 Zhao et al. had reported gene expression profiles of a high metastatic 
cell line MDA-MB-435 transfected with Nm23-H1 while Bosnar et al. overexpressed Nm23 
in oral squamous cell carcinoma (OSSC) derived CAL27 cells.39,40 More recently an 
expression microarray analysis identified EDG2 as a candidate gene that is targeted by 
Nm23-H1 to suppress metastasis in MDA-MB-435 cancer cell line.14,41 The present study 
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was done to elucidate downstream pathways and identify potential new genes involved in 
Nm23-H1 mediated signaling in B cells. Gene expression comparisons were made by cDNA 
microarray analysis to determine genes that are upregulated or downregulated by Nm23-H1 
over-expression in a Burkitt lymphoma derived B-cell line, BJAB. The focus of this study 
was to investigate signaling involved in the regulation of cell cycle and apoptosis, two key 
processes during cancer development.
Gene expression analysis revealed that there was a general reduction of cell cycle regulatory 
proteins including cyclins and cyclin dependent kinase inhibitors and upregulation of 
apoptotic genes which included p53, caspase 3, 9 and Bcl-x. Promoter assays revealed that 
Nm23-H1 indeed reduced the transcriptional activity of the Cyclin D1 promoter in BJAB 
cells suggesting that the functional consequence may be a lower growth rate in cells 
expressing Nm23-H1. Proliferation assays showed that BJAB cells expressing Nm23-H1 had 
a lower growth rate than vector transfected cells. Why would a gene that suppresses 
metastasis, inhibit growth? Perhaps the ability to suppress metastasis and the ability to 
inhibit growth are regulated through two distinct pathways. The answer may lie in the fact 
that cell cycle withdrawal is essential for terminal cell differentiation and that Nm23-H1 
induces cell differentiation.42,43 Transfection of Nm23-H1 in MDA-MB-435 cells resulted 
in reduced growth rate and influenced the differentiation state with the formation of 
organized acinus like structures and synthesis and secretion of basement membrane 
components in a three-dimensional matrix.44 Similarly, PC12 cells overexpressing Nm23-
M1 underwent growth arrest accumulating in the G0/G1 phase of cell cycle in response to 
nerve growth factor (NGF) treatment.45 However, when Nm23-M1 expression was inhibited 
by anti-sense cDNA transfection, the cells displayed a remarkably higher proliferation rate 
and did not differentiate despite NGF treatment.45
A recent finding that MDA-MB-435 cells that express Nm23 showed a reduced ERK 
activation levels compared to control cells, may provide some insight on the molecular level 
as to why these cells have lower proliferation rate.46 Nm23-H1 was shown to interact and 
phosphorylate an ERK1/2 MAP kinase (extracellular signal-regulated kinase mitogen-
activated protein kinase) scaffold protein, kinase suppressor of RAS (KSR).46 It was 
hypothesized that the phosphorylation of KSR by Nm23-H1 alters its scaffold function 
which could lead to reduced ERK activation in response to signaling.46 Since, ERK 
signaling regulates cell cycle progression from G0/G1 to S phase by inducting cyclin D1 
followed by phosphorylation of the retinoblastoma (Rb) protein, it is plausible that Nm23-
H1 targets both upstream event (e.g., ERK activation), and the downstream event (e.g., 
cyclin D induction) to lower the proliferation rate of cells.
The results of our screen also identified the tumor suppressor p53 as a target which was 
transcriptionally upregulated in Nm23-H1 transfected cells. We found that BJAB cells stably 
transfected with Nm23-H1 had an increased susceptibility to apoptosis and that the 
apoptosis seen was p53 dependent as evidenced by the expression of Bax, as well as the 
downstream effector of p53, p21. One of the most interesting questions in the p53 field is 
how a cell makes the decision to undergo growth arrest or apoptosis. It has been proposed 
that p53 may induce two sets of genes upon stress signals.47,48 One set mainly functions in 
cell growth control, such as p21/Waf-1 and GADD45, and the other set acts on apoptosis, 
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such as Bax.49 In this study, we observed that Nm23-H1 is capable of inducing apoptosis in 
a B-cell line where expression of wild-type p53 is enhanced. The resulting apoptosis was 
accompanied by an increase in p53 levels as well as its DNA-binding activity followed by 
Bax expression at the protein level. Further experiments using p53-null cells as well as 
increased expression induced apoptosis in tumor cells via a p53-dependent pathway and 
expression of Bax the downstream effector of p53. Interestingly, upregulation of p21, an 
inhibitor of cyclin/cdk supports the anti-proliferative effect of the Nm23-H1. These findings 
are similar to a recent work where expression of Nm23-H1 in HeLa cells resulted in 
increased levels of p53 triggering the downstream antioxidative pathway.50 Interestingly p53 
has been shown to be a positive regulator of Nm23-H1 in MCF-7 and J7B cells.48,51 This 
raises the possibility whether there is a negative feedback loop between these two proteins as 
our results indicate that Nm23-H1 is able to modulate p53 expression. Here in support of the 
previous finding by Jung et al. we now show that Nm23-H1 can directly interact with p53 
and its DNA binding domain and oligomerization domain and may do so in the absence of 
the intermediate any molecule.31
In conclusion, our microarray data analysis have indentified two important proteins targeted 
by Nm23-H1 that merit investigation in Nm23-H1 mediated pathways in B cells (Fig. 8). 
Overall, our results indicate that Nm23-H1 may have a role in the development of B cell 
cancers. We also show utilization of the p53 dependent pathway resulting in growth arrest 
and apoptosis. By using the pathway specific microarray technology we have now elucidated 
a number of cellular processes which can be modulated by Nm23-H1. Though our proposed 
model (Fig. 8) is not totally complete still we able to propose a specific pathway in our 
current data. Importantly, a thorough investigation of these cellular processes and their 
interaction with Nm23-H1 may be a step forward in enlightening its functional role in the 
context of cell cycle regulation, growth, proliferation and apoptosis.
Materials and Methods
Cell lines and antibodies and constructs
EBV negative Burkitt’s lymphoma BJAB, DG75 cells were provided by Elliott Kieff 
(Brigham and Women’s Hospital, Boston, MA). BJAB-pA3M stable (pZp) and BJAB-
pA3M-Nm23-H1 (clone #6 and clone #10) stable cell lines were grown in RPMI 1640 
medium (Hyclone, Logan, UT) supplemented with 10% bovine growth serum, 2 mM 
Glutamine and 25 U/ml Penicillin/Streptomycin and 300 μg/ml G418 (active concentration).
The p53 reporter plasmid pGL-3 contains 13 copies of p53-binding sites upstream of the 
luciferase gene and was constructed by insertion of p53-binding sequences at EcoRV site of 
the pGL-3 luciferase reporter plasmid.52 The p53 expression vector pC53-C1N3 carries a 
wild-type human p53 gene with a proline polymorphism at residue 73 and is controlled by 
the cytomegalovirus promoter (gift from Gary J. Nabel, National Institutes of Health, 
Bethesda, MD). The pGEX-p53 construct expresses an N-terminal Glutathione S-transferase 
(GST)-p53 fusion protein and was derived from pGEX-2T (Amersham Pharmacia, Inc., 
Piscataway, NJ) by insertion of human p53 cDNA (gift from Gary J. Nabel, National 
Institutes of Health, Bethesda, MD) at the BamHI and EcoRI sites. The pA3M-p53 
expression construct was generated by cloning PCR-amplified p53 cDNA using pGEX-p53 
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as a template into the previously described vector pA3M53 at EcoRI and NotI sites. GST-p53 
deletion constructs were constructed by insertion of PCR fragments into the pGEX-5x-1 
backbone (gift from Shelley L. Berger, The Wistar Institute, Philadelphia, PA).
Two hundred ninety-three cell line was obtained from Jon Aster (Brigham and Woman’s 
Hospital, Boston, MA).54 The p53-null cell line SAOS-2 was derived from a human 
osteosarcoma and was obtained from Jon Aster (Brigham and Women’s Hospital, Boston, 
MA, USA). 293 and SAOS2 cells were grown in DMEM medium (Hyclone, Logan, UT) 
supplemented with 10% bovine growth serum, 2 mM glutamine and 25 U/ml Penicillin/
Streptomycin. The doxycycline regulated p53 inducible 293 cells were grown in DMEM 
medium (Hyclone, Logan, UT) supplemented with 10% bovine growth serum, 2 mM 
Glutamine and 25 U/ml Penicillin/Streptomycin and Puromycin. 9E10 and 12CA5 
hybridoma supernatant was used as an antibody for detection myc-tag and HA-tagged 
proteins, respectively. Anti-p53 antibody was purchased from Santa Cruz Inc., and anti-
rabbit Nm23-H1 antibody was purchased from Seikagaku Corp (Tokyo, Japan). Anti-p21 
and anti-Bax antibodies were purchased from Santa Cruz, CA.
Stable transfection
BJAB cells were transfected by electroporation using a BioRad Gene Pulser II 
electroporator. Ten million cells were collected and washed once in phosphate buffered 
saline. The cells were then resuspended in 400 μl of RPMI 1640 containing DNA (pA3M or 
pA3M-Nm23-H1) normalized to balance total DNA and transfection efficiency was 
determined by GFP expression as an internal control. Once resuspended the cells were 
transferred to a 0.4 cm electroporation cuvettes and electroporated at 975 μF and 220 V. 
Following electroporation the cells were plated in 10 ml of supplemented media and grown 
at 37°C with 5% CO2. Cells were harvested twenty four hours post-transfection, 
resuspended in 1:40 ratio in DMEM supplemented with 1 mg/ml G418, and seeded on 12-
well plates. The antibiotic supplemented medium was changed every 2 d until the 
development of stable, resistant colonies. After 3 w of selection, five resistant, pA3M-
Nm23-H1, and two vector control clones were isolated. The presence of pA3M-Nm23-H1 
was confirmed by western blotting using anti Nm23-H1 and anti-myc specific antibodies as 
well as by florescent microscopy. One of the pA3M-Nm23-H1 clone and one of the vector 
control clone were subjected to further analysis. The pEYFP-Nm23-H1 fusion and pEYFP 
control vector were also used in some experiments. We also use HA-tagged pCDNA-Nm23-
H1 in some of the experiments.
Total cellular RNA isolation, microarray hybridization and analysis
Total cellular RNA was extracted from the clone expressing pA3M-Nm23-H1 and the vector 
control clone. The selected cell clones were thawed incubated in DMEM supplemented with 
10% fetal bovine serum and 300 μg/ml G418 and seeded on Petri dishes, split and collected 
upon 90% confluency. The RNA was isolated using TRIzol Reagent (Invitrogen, Inc., 
Carlsbad, CA) following the manufacturer’s instructions. Isolated total RNA was 
electrophoresed through 1% agarose gel to verify the presence and integrity of rRNA. The 
concentration and purity of RNA were determined from absorbance measurements at 260 
and 280 nm. Additional PCR using primers for intron sequences was preformed to exclude 
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possible DNA contamination. For microarray analyses, the concentration of total RNA was 
adjusted to 2 μg/μl and the standard procedure for preparing the total RNA (15 μg) to be 
hybridized (first- and second-strand cDNA synthesis, synthesis of biotin-labeled cRNA—in 
vitro transcription, fragmentation), was followed as recommended by OligoGEarray 
standard protocol (www.superarray.com/OligoGEArray.php). Labeled and fragmented 
cRNA was further hybridized to probes on oligoGEArray membrane (SuperArray 
Bioscience Corporation, Frederick, MD) according to manufacturer’s instructions. The 
mRNA expression levels were evaluated using the GE Array Expression analysis Suite 5.0 
Software. A comparison analysis was carried out which evaluated the relative change in 
abundance for each transcript.
Generation of doxycycline inducible cell lines for p53 silencing
To generate pSuper-puro-p53 for inducible expression of small interfering RNA targeting 
p53, the annealed oligonucleotides GAT CCC CGA CTC CAG TGG TAA TCT ACT TCA 
AGA GAG TAG ATT ACC ACT GGA GTC TTT TTG GAA A and AGC TTT TCC AAA 
AAG ACT CCA GTG GTA ATC TAC TCT CTT GAA GTA AGA TTA CCA CTG GAG 
TCG GG were ligated into the pSIREN-RetroQ-TetP vector (BD Bioscience, San Jose, CA). 
The constructs, pSuper-puro-p53 along with the control vector pSuper-puro-Luciferase, were 
transfected in 293 cells and then selected with 0.5 μg/ml puromycin (Sigma, St. Louis, MO) 
to get the stable clone.
Real-time PCR
To verify the results of the microarray analysis real-time PCR was preformed (Applied 
Biosystems, Foster City, CA) according the manufacturer’s instructions. Total RNA was 
isolated as described earlier. The cDNA was prepared with 2 μg of total RNA in a total 
volume of 100 μl, using a Superscript II RT kit (Invitrogen, Inc., Carlsbad, CA) according to 
the manufacturer’s instructions. Real-time PCR reactions were performed in 25 μl volume 
with 2.5 μl cDNA, 0.2 μM each primer and SYBR Green PCR Master Mix (Applied 
Biosystems). All PCR reactions were run at 95°C for 10 min, followed by 40 cycles 95°C 
for 15 s, 62°C for 30 s and 60°C for 30 s. Each sample was done in triplicate. The melting 
curve analysis was performed after each run. Validation experiments were done by making 
serial dilution of the cDNA, and calculated using the 2−ΔΔCt method (ΔΔCt = ΔCt (sequence 
of interest) − ΔCt (GAPDH DNA), and ΔCt = Ct (immunoprecipitated DNA) − Ct (input 
DNA), Ct = threshold cycle).55 Target genes Ct values were normalized against endogenous 
control GAPDH. The real-time PCR was performed in triplicates in two independent 
experiments.
Western blotting
Western blotting assays were performed as previously reported.26 Western blots were 
performed using antibodies specific to Nm23-H1, p53, p21 and Bax along with antibodies 
specific to the HA and myc tag and infra red labeled secondary antibodies (Rockland, Inc., 
Gilbertsville, PA). Blots were scanned and signals were detected with an Odyssey Imager 
(LiCor, Inc., Lincoln, NE).56–59
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Electrophoresis mobility shift assays (EMSA)
The probes for the AP-1 binding site within the Cyclin D1 promoter have been previously 
described.26 The probes were end-labeled by Klenow fill-in reaction with [α-32P] dCTP and 
purified with NucTrap Probe Purification Columns (Stratagene, Inc., La Jolla, CA). 
Radioactive probes were diluted in STE (100 mM NaCl, 10 mM Tris pH 7.5, 1 mM EDTA) 
to a final concentration of 100,000 cpm/μl. DNA binding reactions and the preparation of 
nuclear extracts were performed as described previously.26 BJAB cells were used for 
preparing nuclear extract. Invitro translated myc-Nm23-H1 was used. Fifteen micrograms of 
protein from nuclear extracts was mixed with 1 μg poly (dI-dC) (Sigma) in DNA binding 
buffer (20 mM HEPES pH 7.5, 0.01% NP-40, 5.0% glycerol, 10 mM MgCl2, 100 μg of 
bovine serum albumin, 1 mM DTT, 1 mM PMSF, 40 mM KCl) to a total volume of 50 μl 
and incubated at room temperature for 5 min. One microliter of labeled probe was added to 
each reaction followed by an additional 15 min at room temperature. Cold competitors 
(200x) were added prior to the initial incubation at room temperature. Rabbit polyclonal 
antibodies against AP1 and anti-myc ascites were used for supershifting the specific bands. 
DNA-protein complexes were resolved on a non-denaturing 6% PAGE run in 0.5x TBE 
buffer at a constant voltage of 150 V. Following electrophoresis, the gels were dried and 
exposed to a Phosphor Imager Screen (Amersham Biosciences Inc., Piscataway, NJ) for 48–
72 h.
Chromatin immunoprecipitation assay
Nm23-H1 (overexpressed with myc-Nm23-H1) expressing cells were cross-linking with 1% 
formaldehyde for 10 min at room temperature. Cross-linking was stopped by adding 125 
mM glycine to the culture medium. Cells were washed twice with unlabeled phosphate-
buffered saline (PBS) and resuspended in cell lysis buffer containing 5 mM piperazine-N, N-
bis(2-ethanesulfonic acid) (PIPES), KOH, pH 8.0, 85 mM KCl, 0.5% NP-40 and protease 
inhibitors and incubated on ice for 10 min. Cells were dounced for efficient lysis followed 
by centrifugation at 5,000 rpm for 5 min at 4°C. Nuclei were resuspended in nuclei lysis 
buffer, 50 mM Tris, pH 8.0/10 mM EDTA/1% SDS containing protease inhibitors and 
incubated for 10 min. Chromatin were sonicated to an average length of 700 bp and cell 
debris were removed by centrifugation at high speed for 15 min at 4°C. Supernatant 
containing the sonicated chromatin was diluted fivefold with chromatin immunoprecipitation 
dilution buffer containing 0.01% SDS/1.0% Triton X-100/1.2 mM EDTA, 16.7 mM Tris, pH 
8.1/167 mM NaCl including protease inhibitors. Samples were precleared with salmon 
sperm DNA/protein A/Sepharose slurry for 30 min at 4°C with rotation. Supernatants were 
collected after brief centrifugation; 10% of the total supernatant was saved for input control 
and the remaining 90% was divided into fractions: (i) control antibody (Sigma, Inc.,), (ii) 
Rabbit-polyclonal anti Nm23-H1 from Seikagaku Corp (Tokyo, Japan). Immune complex 
was precipitated using salmon sperm DNA/Protein A/Protein G slurry. Beads were then 
washed consecutively with low-salt buffer containing 0.1% SDS/1.0% Triton X-100/2 mM 
EDTA-20 mM Tris, pH 8.1/150 mM NaCl; high-salt buffer containing 0.1% SDS/1.0% 
Triton X-100/2 mM EDTA-20 mM Tris, pH 8.1/500 mM NaCl; LiCl wash buffer containing 
0.25 M LiCl/1.0%NP-40/1% deoxycholate-1 mM EDTA-10 mM Tris, pH 8.0; and twice in 
Tris-EDTA. The complex was eluted using elution buffer containing 1% SDS/0.1 M 
NaHCO3 and reverse cross-linked by adding 0.3 M NaCl at 65°C for 4–5 h. Eluted DNA 
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was precipitated and treated with proteinase K at 45°C for 2 h and was subjected to 
purification. The primers [Forward primer 5′ TCT GAA TGG AAA GCT GAG AAA CAG 
3′ and Reverse Primer 5′ CCC AGG CAG AGG GGA CTA ATA 3′] and it targets 100 bp 
sequence on CyD1 promoter and has AP1 site in the centre Amplified bands were quantified 
using KODAK 1D 3.6 imaging software (Kodak Gel Logic, Rochester, NY).
Glutathione S-transferase (GST) fusion protein preparation, in vitro binding assays, and 
cellular lysate binding
Escherichia coli strain BL21 cells were transformed with pGEX2T-p53 plasmids expressing 
three different truncations of p53 and selected on an ampicillin plate. A culture grown 
overnight from a single colony was inoculated into 500 ml of Luria-Bertani medium and 
grown to mid-exponential phase with shaking. The cells were induced with 1 mM isopropyl-
D-thiogalactopyranoside (IPTG) overnight at 30°C with shaking. The cells were 
subsequently harvested and sonicated, and the protein was solubilized. The lysate was then 
incubated with glutathione-Sepharose beads overnight at 4°C with rotation. The beads were 
collected by centrifugation and washed four times with NETN (20 mM Tris HCl [pH 
8.0]-100 mM NaCl-1 mM EDTA-0.5% Nonidet P-40) containing protease inhibitors. The 
protein-bound beads were stored at 4°C in NETN containing protease inhibitors. The full-
length pA3M clone of the Nm23-H1 gene was transcribed and translated in vitro with [35S]-
methionine-cysteine in the T7 TNT system (Promega, Inc., Madison, WI). The in vitro 
translated proteins were first precleared with glutathione-Sepharose beads in binding buffer 
(1X PBS, 0.1% NP-40, 0.5 mM dithiothreitol, 10% glycerol, supplemented with protease 
inhibitors, 1 mM phenyl-methylsulfonyl fluoride, 2 μg of aprotinin per ml, 1 μg of pepstatin 
A per ml, 2 μg of leupeptin per ml) for 30 min at 4°C with rotation, and the beads were 
removed by centrifugation. A second preclearing was done with GST-bound Glutathione-
Sepharose beads followed for 1 h at 4°C with rotation, with the beads removed by 
centrifugation. The precleared protein was incubated with truncation mutant constructs of 
GST-p53 for 16 h at 4°C with rotation. The beads were then pelleted by centrifugation and 
washed four times with the binding buffer. The beads and bound protein were then denatured 
with sodium dodecyl sulfate (SDS)-β-mercaptoethanol lysis buffer with boiling, followed by 
SDS-polyacrylamide gel electrophoresis (PAGE). The gel was then dried and exposed to a 
storage phosphor screen (Amersham Biosciences Inc., Piscataway, NJ). Western blotting 
using the specific anti-myc antibody was performed to detect Nm23-H1.
Coimmunoprecipitation
Nm23-H1 and p53 were sub-cloned in pCDNA3.1-HA and pA3M-myc respectively by PCR 
amplification of the respective template. The clones were analyzed for integrity by 
restriction digestion and sequence analysis. The pA3M-p53 (Myc-tagged) and pCDNA3.1-
HA-Nm23-H1 constructs were transfected separately into 293 and BJAB cells. Cells were 
harvested 36 h post transfection and lysed in radioimmunoprecipitation assay (RIPA) buffer 
(50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, pH 8.0) with protease 
inhibitors (1 mM phenylmethyl sulfonyl fluoride (PMSF), 10 μg/μl pepstatin, 10 μg/ml 
leupeptin and 10 μg/ml aprotinin). Lysates were centrifuged to remove cell debris and 
precleared using control antibody. Precleared lysates were then incubated with anti-Myc 
antibody (Myc ascites) overnight at 4°C with rotation followed by incubation with protein 
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A/G Sepharose beads at 4°C for 1 h. The resulting immunoprecipitates were collected by 
centrifugation at 2,000 g for 3 min at 4°C and the pellets were washed four times with 1 ml 
of ice-cold RIPA buffer and resuspended in 30 μl of 2 μl SDS protein sample buffer (62.5 
mM Tris, pH 6.8, 40 mM dithiothreitol, 2% SDS, 0.025% bromophenol blue and 10% 
glycerol). The proteins were resolved on 10% SDS-PAGE, transferred to nitrocellulose 
membranes, and subjected to immunodetection of Nm23-H1 using specific HA antibody. 
The same membrane was stripped for the detection of p53 in immunoprecipitation.
Reporter assays
Ten million cells (BJAB or DG75 or 293 cells) were co-transfected with 5 μg Cyclin D1 or 
pG13 promoter construct containing 13 copies of the p53 responsive element kindly 
provided by Dr. Wafik El-Deiry, along with pCMV-Rulc (10:1 ratio) constructs and the 
indicated amounts of pA3M-Nm23-H1. The differences in amount of the Nm23-H1 
construct were adjusted with pA3M vector to keep the total amount of transfected DNA 
constant. Twenty-four h post-transfection, the cells were harvested, washed with PBS, and 
lysed in 300 μl of reporter lysis buffer. A 40 μl aliquot of the lysate was transferred to a 96-
well plate. Luciferase activity was measured using an LMaxII384 luminometer (Molecular 
Devices, Sunnyvale, CA) by injecting 25 μl of luciferase substrate into each well and 
integrating the luminescence for 10 s post-injection. The total protein was measured after 
using stop and glow reagent (Promega Pvt. Ltd., Singapore).
Proliferation assays
For assessing cell proliferation we performed 5,6-carboxyfluorescein diacetate succinimidyl 
ester (CFSE) assay. BJAB, DG75, 293 and SAOS-2 cell lines transfected with pA3M-Nm23-
H1 or pA3M as vector control in experiments. In carboxyfluorescein diacetate succinimidyl 
ester (CFSE) labeling experiments, briefly, 10 million cells were washed and incubated with 
2.5 mM CFSE (Molecular Probes, Inc., Eugene, OR) in PBS for 10 min in the dark at room 
temperature. Unbound CFSE was quenched by the addition of BGS. The labeled cells were 
washed twice with 5% BGS in PBS and re-pelleted at a concentration of 300,000 cells per μl 
in RPMI 1640 medium containing 10% Bovine Growth Serum (BGS). The cells were 
incubated in culture media supplemented with 0.1% fetal bovine serum and assayed at 72 h 
post-staining using a flowcytometer. All flowcytometric analyses were conducted on a 
FACS-Caliber cytometer using cell quest software (Becton Dickinson Inc., San Jose, CA).
Apoptosis assays
BJAB, DG75, 293 and SAOS-2 cells were transfected with YFP-Nm23-H1 along with YFP 
vector clone. Transfected cells were incubated in growth medium for approximately 24 h to 
allow for sufficient levels of transgene expression. In cell viability analysis experiments, 
cells were collected, washed, and incubated with 10 μl 7-aminoactinomycin D (7AAD) 
(Pharmingen Inc., San Jose, CA) for 10 min in the dark at 4°C. Five hundred micro liters of 
PBS was then added, and cells were taken for FACS analysis immediately. 7AAD positive 
cells were counted as dead cells.
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Figure 1. 
Expression of Nm23-H1 in different BJAB cell lines and the Oligo GE array analysis. 
Western blot showed about 20-fold overexpression of Nm23-H1 protein in clone 10 cells 
(used for experiments) compared to clone 6 cells (highly metastatic). The same blot was 
stripped and probed with actin to demonstrate equal loading. As shown in same Figure, RT-
PCR analysis showed 2.2-fold overexpression of nm23 transcript in clone 10 cell line 
compared to clone 6. The right panel showing the trend of the individual array of the specific 
pathway (Apoptosis, cell cycle and p53 pathway).
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Figure 2. 
Nm23-H1 reduces the transcriptional activity of the Cyclin D1 promoter in B cells and 
binding to the specific site in the promoter. (A) pGL2-Cyclin D1 promoter was co-
transfected with increasing amounts of pA3M-Nm23-H1, the pCMV-Rlu promoter and 24 h 
post-transfection BJAB or DG75 or 293 cells were harvested for dual luciferase assay. 
Increasing amounts of Nm23-H1 showed a dose-dependent decrease of promoter activity. 
(B) Different truncation along with the full length Cyclin D1 was shown in the left top of the 
figure. Either the full length or the truncated one pGL2-Cyclin D1 promoter was co-
transfected with pA3M-Nm23-H1 and the CMV-Rlu promoter and 24 h post-transfection 
BJAB or DG 75 or 293 cells were harvested for dual luciferase assay. The promoters lacking 
AP1 sites (mutant number 4, 5 and 6) showed a lack of downregulation activity in presence 
of Nm23-H1.
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Figure 3. 
Nm23-H1 forms a complex with the AP1 transcription factor bound to its binding site. 
EMSA showed a specific AP1 shift observed when nuclear extract was added to reaction 
with labeled AP1 specific probe. The specificity of this shift was verified through the 
disappearance of the shift in the presence of mutant AP1 probe or specific cold competitor 
(A and compare lanes 1, 2 with 3 or 4). The shift was not disrupted when we used a non-
specific cold competitor (lane 5). The mobility of the AP1 probe was reduced by the 
presence of in vitro translated Nm23-H1 (lane 6). There was no apparent change on effect 
when we used un-programmed the rabbit reticulocytes (lane 7). The presence of Nm23-H1 
in the complex was verified by additional supershifting in the presence of anti-myc antibody 
(1 μg) used to detect Nm23-H1 (lane 8). The presence of AP1 was shown by AP1-specific 
supershift (lane 9). Additionally, no specific supershift was observed with when the IgG 
control antibody was used (lane 10). (B) Chromatin from Nm23-H1 overexpressing cells 
was cross-linked with 1% formaldehyde followed by washing with PBS. Cell nuclei were 
released from these cells followed by sonication of chromatin to approximately 700 bp. 
Sonicated chromatin were diluted with chromatin immunoprecipitation dilution buffer. 
Chromatin was immunoprecipitated using antibodies specific for Nm23-H1. The primer sets 
mentioned in material and methods were used to amplify the regions 100 bp sequence on 
CyD1 promoter containing the AP1 cognate sequence. Amplified bands were quantitated 
and the relative amounts were calculated. Lane 1, DNA purified from 10% of the total 
chromatin; lane 2, DNA from chromatin immunoprecipitated with rabbit polyclonal anti-
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Nm23-H1; lane 3, DNA from chromatin immunoprecipitated with control immunoglobulin 
G antibody (Sigma, Inc.).
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Figure 4. 
Nm23-H1 enhances the transcriptional activity of p53 in B cells. (A) pG13 promoter was co-
transfected with increasing amounts of pA3M-Nm23-H1 and the CMV-Rlu promoter and 24 
h post-transfection BJAB or DG 75 or 293 and SAOS2 cells were harvested for dual 
luciferase assay. Increasing amounts of Nm23-H1 showed a dose-dependent upregulation of 
promoter activity.
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Figure 5. 
Nm23-H1 specifically interacts with the DNA-binding domain of p53. (A) A schematic 
representation of Full length domains along with the different truncations. (B) In vitro-
translated Nm23-H1 protein was 35S labelled and tested for binding with a number of 
truncated mutants of GST-p53 constructs mapping the binding region (Full length, 1–80, 
100–300 and 300–393). Relative binding levels are shown in the bar diagrams. (C) Lysates 
from Nm23-H1 expressing BJAB and 293 cells were incubated with the GST-p53 FL and 
the results of the binding are shown.
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Figure 6. 
Nm23-H1 expressing cells have reduced proliferation and prone to apoptosis. (A) BJAB 
cells transfected with either with pEYFP or with pEYFP-Nm23-H1 and stained with 7AAD 
to detect the apoptotic cell. About 40% of the cells were both Nm23-H1 and 7AAD positive. 
Similarly, the results from 293 and DG75 assays shown in the table had increased 7AAD 
suggesting increased apoptosis. (B) BJAB cells transfected either with vector alone or with 
pA3M-Nm23-H1 and stained with CFSE for determination of the level of proliferation. The 
Nm23-H1 expressing cells showed a reduced level of proliferation.
Choudhuri et al. Page 25
Cancer Biol Ther. Author manuscript; available in PMC 2018 May 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. 
Nm23-H1 can induce apoptosis in a p53 dependent manner (A) Tet-off inducible p53-
expressing 293 cells were transfected with Nm23-H1 and p53. Bax and p21 levels were 
detected by western blot in the absence and presence of tetracycline. (B) YFP tagged Nm23-
H1 and pGEYFP were transfected and stained with 7AAD. The result showed there was 
reduced apoptosis in cells were knocked down for p53 using the shRNA strategy. Again 
cotransfection with p53 and Nm23-H1 showed a marked increase of apoptotic cell 
population.
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Figure 8. 
Schematic showing the role of Nm23-H1 in cell cycle regulation and apoptosis. A 
Hypothetical model shows the putative mechanisms for Nm23-H1 induced cell cycle arrest 
and subsequent apoptosis in p53 dependent pathway.
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Table 1
List of cellular genes which showed modulation of expression in presence of Nm23-H1 on micro array 
analysis and were validated by real time PCR
Genes Fold Change
Selected Genes Upregulated by Nm23-H1
Caspase 9, apoptosis-related cysteine protease 16.20
Tumor necrosis factor receptor superfamily, member 25 8.36
p53 Tumor protein (Li-Fraumeni syndrome) 2.16
BCL2-associated X protein 2.14
Caspase 3, apoptosis-related cysteine protease 2.67
Selected Genes Downregulated by Nm23-H1
Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 16
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 11
Cyclin D 6
Cyclin A2 5.88
Cyclin B 5
Cyclin E2 2.7
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